NCT06797115View on ClinicalTrials.gov

Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
T2DM
Interventions
DRUG

SGLT-2 inhibitor

T2D patients for whom, in addition to administering any existing antidiabetic regimen, the treating physician decided to initiate SGLT-2 inhibitor therapy (empagliflozin or dapagliflozin) based on standard clinical indications.

Trial Locations (1)

H-7624

2nd Department of Medicine and Nephrology-Diabetes Center, University of Pécs Medical School, Pécs

All Listed Sponsors
lead

University of Pecs

OTHER